Kyntra Bio, Inc. Common Stock (KYNB) Stock Price

KYNBStock

$8.10−28.62%52W

Market Cap$32.80M

P/E0.16x

PEG Ratio—

Div yield—

Beta1.04

KYNB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-8.81%

Price vs S&P 500 (4W)11.36%

VGM Score62.24

P/E Ratio (Annual)0.16x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-64.23%

Cash Flow / Share (Quarterly)$-5.29

Price vs S&P 500 (YTD)-21.07%

Gross Margin (TTM)40.70%

Net Profit Margin (TTM)2199.42%

EPS (TTM)$40.46

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$40.46

Revenue Growth (5Y)-48.41%

EPS (Annual)$45.38

ROI (Annual)-127.92%

Gross Margin (Annual)91.37%

Net Profit Margin (5Y Avg)432.73%

Cash / Share (Quarterly)$21.55

P/E Basic Excl Extra (TTM)0.17x

Revenue Growth QoQ (YoY)36.47%

P/E Normalized (Annual)0.16x

ROA (Last FY)153.40%

Revenue Growth TTM (YoY)-92.77%

EBITD / Share (TTM)$-12.60

ROE (5Y Avg)-47.66%

Operating Margin (TTM)-690.63%

Cash Flow / Share (Annual)$-1.19

P/B Ratio1.08x

Net Income / Employee (Annual)$5,395,600

EV / Revenue (TTM)1.45x

Net Interest Coverage (TTM)-9.02x

ROA (TTM)120.24%

EPS Incl Extra (Annual)$45.38

Current Ratio (Annual)3.39x

Quick Ratio (Quarterly)3.44x

3-Month Avg Trading Volume0.02M

52-Week Price Return-28.62%

P/E Incl Extra (TTM)0.17x

Revenue / Employee (TTM)$218,800

P/S Ratio (Annual)4.43x

Asset Turnover (Annual)0.05x

52-Week High$12.60

Operating Margin (5Y Avg)-375.53%

EPS Excl Extra (Annual)$45.38

CapEx CAGR (5Y)-60.58%

26-Week Price Return2.44%

Quick Ratio (Annual)3.23x

13-Week Price Return14.99%

Total Debt / Equity (Annual)0.08x

Current Ratio (Quarterly)3.61x

Enterprise Value$10.75M

Revenue / Share Growth (5Y)-4.07%

Asset Turnover (TTM)0.05x

Revenue / Employee (Annual)$189,400

Inventory Turnover (Annual)0.16x

Pretax Margin (Annual)-905.19%

Cash / Share (Annual)$21.99

3-Month Return Std Dev37.15%

Gross Margin (5Y Avg)69.60%

Net Income / Employee (TTM)$4,812,200

ROE (Last FY)-138.69%

Net Interest Coverage (Annual)-9.72x

EPS Basic Excl Extra (Annual)$45.38

P/FCF (TTM)1.85x

Receivables Turnover (TTM)2.87x

Total Debt / Equity (Quarterly)0.59x

EPS Incl Extra (TTM)$40.46

Receivables Turnover (Annual)18.48x

ROI (TTM)-256.45%

P/S Ratio (TTM)3.83x

Pretax Margin (5Y Avg)-394.97%

Revenue / Share (Annual)$1.59

Price vs S&P 500 (52W)-46.93%

P/E Ratio (TTM)0.17x

EPS Growth TTM (YoY)3265.69%

Year-to-Date Return-9.11%

5-Day Price Return13.84%

EPS Normalized (Annual)$45.38

ROA (5Y Avg)-4.30%

Net Profit Margin (Annual)2848.63%

Month-to-Date Return18.57%

EBITD / Share (Annual)$-12.79

Operating Margin (Annual)-814.88%

LT Debt / Equity (Annual)0.08x

ROI (5Y Avg)-42.66%

P/E Excl Extra (TTM)0.17x

LT Debt / Equity (Quarterly)0.59x

EPS Basic Excl Extra (TTM)$40.46

Inventory Turnover (TTM)1.35x

Pretax Margin (TTM)-761.70%

Price vs S&P 500 (13W)12.19%

Beta1.04x

P/FCF (Annual)0.37x

Revenue / Share (TTM)$1.84

ROE (TTM)-290.91%

52-Week Low$6.32

vGradeA

gGradeC

mGradeC

vgmGradeB

KYNB Earnings Surprise History

Q2 25-1.88est. 1.00

Q3 2549.61est. -4.00

Q4 25-3.51est. -3.88

Q1 26-3.76est. -3.35

Q2 26-4.69est. -3.18

KYNB Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

4.11

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
KYNBKyntra Bio, Inc. Common Stock	A	C	C	$8.10
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Kyntra Bio, Inc. Common Stock

Kyntra Bio Inc is a biopharmaceutical company developing novel therapies for oncology and rare diseases. Its pipeline includes Roxadustat and FG-3246, targeting indications such as lower-risk myelodysplastic syndrome-associated anemia and metastatic castration-resistant prostate cancer.